1087systems is developing a platform for high-throughput label-free cytometry based on newly-available optical components. 1087systems is founded by serial entrepreneur Matthias Wagner and uses Cambridge Biolabs for their biology laboratory needs.
Actualiti starts science & technology based companies. Thier strategy’s focus is on quick to market life science integrated opportunities, those without burdensome clinical and regulatory barriers. Actualiti partners with technology originators, emerging companies, and established organizations to perform diligence & to build the scientific, intellectual property, and business foundations necessary to attract resources to a project.
Adherean is dedicated to helping patients stay on track with their treatment plans. Using a combination of biological engineering and behavioral economics, the Adherean Healthcheck technology turns the outcome of disposable medication tests into secret reward codes patients can remotely exchange for instant incentives.
Advirna develops innovative solutions for efficient delivery of polynucleotides in vivo. Advirna’s proprietary RNAi platform based on self-deliverable RNAi technology has broad applications in Life Sciences. Self-deliverable RNAi provides researchers with new and efficient tools to specifically knock-down genes in living cells (both in vitro and in vivo) as well as to develop a pipeline of drug products to treat a wide array of human diseases.
Anchor Therapeutics is a pre-clinical stage drug discovery and development company founded to advance pepducin technology, a novel approach to defining allosteric modulators of G-protein coupled receptors (GPCRs), the largest and richest family of drug targets . Our flexible, modular business model facilitates a range of collaborations from discovery of in vitro research tools to pepducin-based pharmaceutical candidates. Anchor has broad exclusivity to pepducin technology intellectual property and has augmented its intellectual property position through its own portfolio of patent applications.
Aura BioSciences develops a novel technology based on NanoSphere Particles (“NSPs”), consisting of recombinant proteins, that enables the selective targeting of tumor metastases while sparing normal epithelium. Aura’s technology is based on a novel and highly-selective Universal Tumor Targeting (“UTT”) phenomenon recently discovered at the National Cancer Institute (NCI.) The recombinant proteins are produced via well-known methods similar to vaccine manufacture, and self-assembled into empty 72-sided polygons of 60nm diameter.
Axios Biosciences is a start-up company developing oncology therapeutics active in the tumor microenvironment, where tumors intimately interact with normal cells. The Company’s high-throughput microenvironment screening technology combined with our cancer genomics capabilities represent a unique strategy to discover novel therapeutics. Axios Biosciences’ core approach recently published in Nature Medicine and is being leveraged to help pick winners for pharmaceutical and biotechnology companies. This strategy and technology increases the probability of identifying compounds with enhanced microenvironment activity.
BioMolecular Therapeutics, Inc. is a new Seoul-based RNAi therapeutics company with a proprietary technology designed to reduce significantly deleterious side effects triggered by conventional siRNA. The company is currently developing a novel RNAi therapeutic for age-related macular degeneration (AMD), based on its asymmetric shorter-duplex siRNA (asiRNA) technology.
Energesis Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of drugs to treat obesity, diabetes, and related metabolic diseases. Their novel approach seeks to increase the body’s energy expenditure, the first to specifically target the expenditure rather than the intake side of the weight maintenance equation.
Izon has developed accurate instrumentation for nanoscale particle analysis. The instrument systems, the qNano and qViro, are now in use in a wide range of research institutes and universities around the world. The basis of Izon’s instrumentation is a unique, dynamically tunable nanopore technology platform which utilises a technology called SIOS (Scanning Ion Occlusion Sensing). This technology platform is world-leading in offering an affordable, robust and highly flexible technology for real-time particle detection, quantitation and characterisation of individual particles at the nanoscale, across a wide range of applications. These applications include sizing, size distribution measurement, concentration analysis and real-time particle-particle interaction monitoring.
PCL focuses on developing innovative technologies, such as highly sensitive protein microarray platform, and RNA-based diagnostics and therapeutics. The team has already developed highly sensitive and specific diagnostics protein chips extremely useful for blood bank screening of many infectious diseases, such as HIV, HCV, and HBV. PCL also provides technology-oriented services, including: (1) Sol-gel chip spotting/Assay service; (2) aptamer generation against proteins, small molecules, or cells; and (3) Nimblegen microarray services.
January 18, 2012
Cambridge Biolabs congratulates our client RaNA Therapeutics on their recent financing. RaNA announced the closing of a Series A round of $20.7 by Atlas Venture, SR One, and Monsanto Co., with participation from Partners Innovation Fund. RaNA came out of stealth mode with the exciting news that it has met its early milestones and enabled its platform. This technology was invented by MGH researcher Dr. Jeannie Lee and allows for selective activation of target genes and expression of therapeutic factors by targeting a type of regulatory RNA called long non-coding RNA (lncRNA).
View the MassHighTech press release here.
RaNA Therapeutics is an Atlas Ventures portfolio company under management of Art Krieg, who was the Entrepreneur in Residence there before starting RaNA.
Vedantra Pharmaceuticals is a spin-out from the laboratory of Prof. Darrell Irvine at MIT. Dr. Irvine’s lab has developed a novel method of making stable, crosslinked, multilammellar lipid nanoparticles that encapsulate and or display antigens and adjuvants for delivery to the cells of the immune system.
ViThera Pharmaceuticals harnesses the synthetic potential of bacteria to produce therapeutic molecules within the body. Recent research highlights the potential of a body’s microbiome (the entirety of its bacterial flora) to influence health and disease in profound ways. For example, certain probiotic strains of bacteria ameliorate diseases of the digestive tract including Inflammatory Bowel Diseases (IBD) like Crohn’s Disease and Ulcerative Colitis. ViThera aims to engineer added pharmaceutical benefits to these bacteria.
Ymir Genomics is using innovative proprietary methods to discover novel disease-linked non-coding RNAs for diagnostic and therapeutic applications.